Search
COVID19 Clinical Trials in Richmond, VA
A listing of 3 COVID19 clinical trials in Richmond, VA actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 3 of 3
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
COVID19
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
The city of Richmond, Virginia, currently has 3 active clinical trials seeking participants for COVID19 research studies.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Stroke Clinical Study
Recruiting
A clinical study for people that suffer with Stroke
Conditions:
Stroke
Featured Trial
Chronic Kidney Disease (CKD) Clinical Study
Recruiting
A clinical study for people that suffer with Chronic Kidney Disease (CKD)
Conditions:
Chronic Kidney Disease (CKD)
Featured Trial
Ischemic heart disease (IHD) Clinical Study
Recruiting
A clinical study for people that suffer with Ischemic heart disease (IHD)
Conditions:
Ischemic heart disease (IHD)
A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults
Recruiting
The purpose of this trial is to assess the safety and relative efficacy of CVXGA (CVXGA50), a KP.2 containing vaccine, compared to COMIRNATY® (COVID-19 Vaccine, mRNA; 2024-2025 Formula), a currently approved COVID-19 vaccine in the prevention of symptomatic, RT-PCR-confirmed SARS-CoV-2 infection. The trial will enroll up to 10016 healthy participants.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/14/2025
Locations: Clinical Research Partners LLC, Richmond, Virginia
Conditions: COVID-19
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
Recruiting
This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection.
It also contains a sub-study to enroll patients with severe COVID-19.
Gender:
ALL
Ages:
All
Trial Updated:
11/18/2024
Locations: VCU Health System, Richmond, Virginia
Conditions: Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age
Recruiting
The primary objective of the study is to characterize the concentrations of casirivimab+imdevimab in serum over time after a single subcutaneous (SC) administration
The secondary objectives of the study are:
To assess the safety and tolerability of SC or single administration of casirivimab+imdevimab
To assess the occurrence of grade ≥3 injection site reactions and grade ≥3 hypersensitivity reactions, in participants treated with SC doses of casirivimab+imdevimab
To assess the immunogenicity o... Read More
Gender:
All
Ages:
12 years and below
Trial Updated:
12/06/2021
Locations: Regeneron Research Site, Richmond, Virginia
Conditions: COVID-19
1 - 3 of 3